IL-WALGREENS
Walgreens today announced the launch of myWalgreens, a complete reinvention of its customer loyalty program to offer customers extensive new benefits, including the fastest same-day retail pickup offering available today*. Customers can now shop online and on a fully-redesigned mobile app for health and wellness items, and then pick them up in the store, curbside or at the drive-thru in as little as 30 minutes.**
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201119005676/en/
Walgreens has the nation’s largest health and wellbeing-centered customer loyalty program, with more than 100 million members. It’s now easier than ever for its members to stay well, shop conveniently and save money and time seamlessly across more than 9,000 stores, Walgreens.com and the mobile app.
The new benefits are in addition to many others already offered by Walgreens. These include an at-home delivery service through DoorDash and Postmates and a Prescription Savings Club with up to 80 percent off cash retail prices.
myWalgreens members can sign up quickly and easily for no cost, and will now receive:
- One percent Walgreens Cash rewards storewide
- Five percent Walgreens Cash rewards on Walgreens branded products
- “Only for you” exclusive deals
Additionally, the mobile app now features a broad range of health and wellness services for customers and patients, including a 24/7 pharmacy chat, access to find and book medical care and vaccination appointments, personalized health and wellness advice, real-time flu alerts and more. The previous version of the app is already very popular, and has been downloaded more than 65 million times.
“As America’s community pharmacy, Walgreens is delivering an unparalleled experience to help customers and patients manage their health and wellbeing during the most severe health crisis of our lifetimes,” said John Standley, Walgreens president. “As always, our more than 25,000 community pharmacists remain at the core of our offering. Our pharmacists and patient care teams do far more than just filling prescriptions – they provide trusted advice, personalized support and a vast range of services.”
The debut of myWalgreens marks another milestone in the company’s digital transformation. Walgreens delivers customers more and more benefits and a highly-personalized experience by working with the very best technology and customer-insight partners, including Microsoft, Adobe and Epsilon.
Online or on the app, myWalgreens members can:
Save Time and Increase Convenience
- Shop a full assortment of more than 27,000 items, including everyday health and wellness and over-the-counter essentials, as well as photos
- Add a payment method to their digital wallet for faster contactless checkout
- Redeem Walgreens Cash rewards instantly at checkout
- Choose digital receipts for quick contactless checkout and to track purchases
Stay Healthy
- Earn bonus Walgreens Cash rewards for achieving health goals
- Receive daily, personalized recommendations for health and wellness, as well as real-time local environment and health forecasts
Help Communities
- Donate their Walgreens Cash rewards to charity (the eligible charity organizations will rotate, beginning with the Full Plate Project , a program of Comic Relief U.S.’ Red Nose Day which works to end child poverty)
Starting today, current Walgreens Balance Rewards members can transfer their membership to myWalgreens at mywalgreens.com. Current Balance Rewards members have until January 31, 2021 to sign up for myWalgreens to ensure that existing rewards roll over to the new program. Over the next several months, myWalgreens will announce even more benefits for customers and patients.
Click here for myWalgreens press kit, including a logo, images and app screenshots.
About Walgreens
Walgreens (www.walgreens.com ) is included in the Retail Pharmacy USA Division of Walgreens Boots Alliance, Inc. (Nasdaq: WBA), a global leader in retail and wholesale pharmacy. As America’s most loved pharmacy, health and beauty company, Walgreens purpose is to champion the health and wellbeing of every community in America. Operating more than 9,000 retail locations across America, Puerto Rico and the U.S. Virgin Islands, Walgreens is proud to be a neighborhood health destination serving approximately 8 million customers each day. Walgreens pharmacists play a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services. To best meet the needs of customers and patients, Walgreens offers a true omnichannel experience, with platforms bringing together physical and digital, supported by the latest technology to deliver high-quality products and services in local communities nationwide.
* As compared to national omni-channel food and pharmacy mass retailers that offer store pick-up free-of-charge.
** For Walgreens store locations that are not open 24 hours, orders must be placed at least one hour prior to store closing in order to be eligible. Otherwise, order will be ready the following business day. Customer will be notified via email when order is ready for pickup and will be provided instructions for a drive-up experience that complies with social distancing guidelines. Orders are not guaranteed to be ready within the 30-minute time window and may be subject to change or substitution depending on product availability at the time order is placed. Orders with age-restricted items may only be picked up in store. Prescription orders not eligible but may be ordered through Walgreens Express®. To find the location and hours of a Walgreens store near you, visit Walgreens.com/FindAStore.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201119005676/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Virometix AG Announces Completion of $15 Million Financing Round to Advance Development of V-212 and Next-Generation Synthetic Vaccines13.11.2025 07:00:00 CET | Press release
Virometix AG, a clinical-stage biotechnology company pioneering fully synthetic vaccines, today announced the completion of a $15 million financing round from existing shareholders. The funds will support continued clinical and development activities for V-212, Virometix’s lead serotype-independent pneumococcal vaccine candidate, currently in Phase I clinical evaluation. Proceeds from the financing will be used to: Advance the ongoing Phase I clinical trial of V-212, with topline results expected in Q1 2026. Prepare for a planned Phase Ib combination trial evaluating V-212 with an approved pneumococcal conjugate vaccine (PCV). Complete OPK assay validation to support immunogenicity and functional data read-outs. Implement platform enhancements to the company’s proprietary Synthetic Virus-Like Particle (SVLP) technology. Progress next-generation serotype-independent pneumococcal vaccine programs toward preclinical development. “This financing demonstrates the continued confidence and co
IMEC Achieves a World-record GaN Breakdown Voltage Exceeding 650 V on Shin-Etsu Chemical’s 300-mm QST™ Substrate13.11.2025 05:00:00 CET | Press release
The QSTTM substrate*1, a 300-mm GaN growth substrate that Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed, has been adopted for the 300-mm GaN power device development program at IMEC*2, where sample evaluation is in progress. In the evaluation, the 5 µm-thick HEMT*3 device using a QSTTM substrate achieved a record-breaking voltage resistance exceeding 650 V for a 300mm substrate. Shin-Etsu Chemical, licensed by QROMIS, Inc. (Head office: CA, U.S.A, CEO: Cem Basceri, hereafter "QROMIS"), manufactures 150-mm and 200-mm QST™ substrates, as well as GaN-on-QST™ epitaxial substrates of various diameters. In September 2024, we started providing 300-mm QST™ samples in a joint initiative with QROMIS. Furthermore, Shin-Etsu Chemical and QROMIS have established a close partnership to provide 300-mm QST™ substrates for the state-of-the-art 300-mm CMOS fab of IMEC, which is based in Leuven, Belgium. IMEC is a 300-mm GaN pow
DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth13.11.2025 04:00:00 CET | Press release
MoU signed at the Singapore Fintech Festival 2025 covers several areas of strategic cooperation to scale digital payments, strengthen connectivity and advance fintech innovationPartnership enables DBS PayLah! users to scan Alipay+ QR codes to pay at more than 150 million merchants across over 100 markets DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/ From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International The collaboration will leverage DBS’ digita
LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 01:00:00 CET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 01:00:00 CET | Press release
Targeting edge LLM applications, accelerating edge AI ecosystem development VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Cora
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
